Monte Rosa Therapeutics Inc.

1 day ago · defenseworld.net

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a

19 days ago · seekingalpha.com

Monte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and milestone payments from its outlicensed flagship asset MRT-6160. MRT-6160, targeting autoimmune diseases, offers differentiated safety and oral convenience, with Phase 2 results as the key near-term catalyst for GLUE. GLUE maintains a robust $626 million cash position, providing a 3.5-year runway and cushioning downside risk amid high clinical trial expenses.

21 days ago · globenewswire.com

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D.

2 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.

3 months ago · fool.com

This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.

3 months ago · seekingalpha.com

Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for MRT-8102 and MRT-6160, but lacks Phase 2 proof-of-concept results to fully derisk programs. Significant cash runway ($675m) and milestone-rich deals provide operational security while awaiting pivotal clinical readouts and potential Novartis milestones.

5 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.57 per share a year ago.

5 months ago · fool.com

A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17.64 per share on April 14, 2026. The sale represented 1.30% of their direct common stock holdings, reducing their directly held common shares from 613,471 to 605,471.

6 months ago · defenseworld.net

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation

6 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.